Zacks: Analysts Expect Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $240,000.00
Equities research analysts expect that Abeona Therapeutics Inc (NASDAQ:ABEO) will post $240,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Abeona Therapeutics’ earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $200,000.00. Abeona Therapeutics posted sales of $260,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 7.7%. The company is expected to announce its next earnings results on Friday, March 30th.
According to Zacks, analysts expect that Abeona Therapeutics will report full year sales of $240,000.00 for the current financial year, with estimates ranging from $800,000.00 to $900,000.00. For the next year, analysts expect that the business will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Abeona Therapeutics.
Several analysts recently weighed in on ABEO shares. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Jefferies Group reiterated a “buy” rating and issued a $28.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Maxim Group set a $35.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Monday, November 20th. Finally, SunTrust Banks started coverage on shares of Abeona Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 target price for the company. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Abeona Therapeutics presently has an average rating of “Buy” and an average target price of $27.11.
Several large investors have recently bought and sold shares of the business. Viking Global Investors LP grew its stake in shares of Abeona Therapeutics by 80.5% in the fourth quarter. Viking Global Investors LP now owns 4,040,727 shares of the biopharmaceutical company’s stock worth $64,046,000 after acquiring an additional 1,802,007 shares in the last quarter. BlackRock Inc. grew its stake in shares of Abeona Therapeutics by 15.1% in the fourth quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock worth $29,614,000 after acquiring an additional 245,217 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Abeona Therapeutics by 11.2% in the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after acquiring an additional 108,730 shares in the last quarter. State Street Corp acquired a new position in shares of Abeona Therapeutics in the second quarter worth $1,900,000. Finally, Geode Capital Management LLC grew its stake in shares of Abeona Therapeutics by 11.4% in the fourth quarter. Geode Capital Management LLC now owns 277,958 shares of the biopharmaceutical company’s stock worth $4,405,000 after acquiring an additional 28,498 shares in the last quarter. Institutional investors and hedge funds own 62.64% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/03/05/zacks-analysts-expect-abeona-therapeutics-inc-abeo-will-post-quarterly-sales-of-240000-00.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.